BridgeMD
New treatment option for Vaping
Official title Behavioral Intervention for Youth to Promote Vaping Cessation
ClinicalTrials.gov ID: NCT06765291
What this study is testing
- What it's testing
- This study will test the hypothesis that the QuitVaping (QV) intervention and additional texting support will improve nicotine abstinence rates in adolescents as compared to Enhanced Usual Care (EUC: education about nicotine, vaping and addiction, advice to quit vaping, referral to TIQ texting support). Approximately 400 adolescents will be randomly assigned to one of two arms (1) QuitVaping intervention plus texting support to quit vaping and (2) EUC only.
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 14 to 19
You may be able to join if
- Age 14-19 inclusive
- Self-report of at least weekly nicotine vaping (or use of other non combusted nicotine products, "vaping") for the prior ≥3 months
- Self-report of no regular combusted tobacco use (i.e., 5 or more days of smoke smoked tobacco use per week) prior to enrollment and exhaled CO \<10...
- Report willingness to try to quit or reduce vaping in the next 30 days
- Able to understand study procedures and read and write in English or Spanish
You likely can't join if
- Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion)
- Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study
- Unwilling to provide saliva or urine samples
- Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol
See the full eligibility criteria
- Age 14-19 inclusive
- Self-report of at least weekly nicotine vaping (or use of other non combusted nicotine products, "vaping") for the prior ≥3 months
- Self-report of no regular combusted tobacco use (i.e., 5 or more days of smoke smoked tobacco use per week) prior to enrollment and exhaled CO \<10 ppm for those with an in person baseline visit
- Report willingness to try to quit or reduce vaping in the next 30 days
- Able to understand study procedures and read and write in English or Spanish
- Have a parent or legal guardian who is able to participate in the opt out process
- Competent and willing to provide written informed consent (if age 18) or assent (if under 18)
- Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion)
- Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study
- Unwilling to provide saliva or urine samples
- Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol
The study team makes the final eligibility decision.
Where it's taking place
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 14 years to 19 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Boston, Massachusetts, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.